Rispoval RS + PI3 IntraNasal
Active substance
ATC code
Species
Cattle.
Indications
For vaccination with Rispoval RS+PI3 IntraNasal only:
For active immunisation of maternally derived antibody positive or negative calves from 9 days of age against BRSV and PI3V, to reduce the mean titre and duration of excretion of both viruses.
Onset of immunity: 5 days for BRSV and 10 days for PI3V after a single vaccination. Duration of immunity: 12 weeks after a single vaccination. The duration of protective immunity against the PI3V fraction may be reduced in MDA positive calves vaccinated before 3 weeks of age.
For primary vaccination using Rispoval RS/Pi3 IntraNasal and booster vaccination with Rispoval 2/BRSV + Pi3*, refer to the Rispoval 2/BRSV Pi3* product information for specific details on indications.
* Where this veterinary medicinal product is authorised.
Dose to be administered and administration route
Dose: 2 ml.
Route: nasal use.
Reconstitution of the vaccine:
Reconstitute the 1 dose and 5 dose presentations by aseptically adding the solvent to the vial containing the lyophilisate. Shake well before use.
Reconstitute the 25 dose presentation by mixing the lyophilised fraction with the solvent in 2 steps:
1. Inject 10 ml of the solvent on the lyophilised plug in the vial containing the lyophilisate.
2. Shake well and extract the reconstituted lyophilised fraction from the vial and mix with the remaining solvent in the liquid fraction vial. Shake well before use.
Reconstituted product: pink to orange liquid, which might contain a loose resuspendable sediment.
Vaccination programme:
Basic vaccination: A single dose of 2 ml of reconstituted vaccine should be given using the intranasal applicator available from Zoetis to cattle from the age of 9 days. It is recommended to change applicators between animals to avoid transmitting infectious organisms.
For primary vaccination using Rispoval RS/Pi3 IntraNasal and booster vaccination with Rispoval 2/BRSV + Pi3*, refer to the Rispoval 2/BRSV Pi3* product information for specific details on vaccination programme.
* Where this veterinary medicinal product is authorised.
Adverse reactions
Cattle:
|
Rare (1 to 10 animals / 10,000 animals treated): |
Hypersensitivity reaction (e.g. anaphylactic-type reaction) |
Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or the national competent authority via the national reporting system. See the package leaflet for respective contact details.
TRUSTED SOURCE
